We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

Back to rankings

90 hedge funds and large institutions have $174M invested in BioSpecifics Technologies Corp. in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 37 increasing their positions, 30 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 30

11% more capital invested

Capital invested by funds: $156M → $174M (+$17.4M)

0% more funds holding

Funds holding: 90 → 90 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
90
Holders Change
–
Holders Change %
0%
% of All Funds
2.4%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
6
Increased
37
Reduced
30
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NC
Northpointe Capital
Michigan
+$4.97M
2
EAM
Eagle Asset Management
Florida
+$2.66M
3
GC
Globeflex Capital
California
+$1.41M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.22M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$839K

Top Sellers

Rank Fund Capital Flow
1
RCMC
RK Capital Management (Colorado)
Colorado
-$3.44M
2
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$3.06M
3
NI
Numeric Investors
Massachusetts
-$2.34M
4
BIM
Bogle Investment Management
Massachusetts
-$1.38M
5
SCM
Stonepine Capital Management
Oregon
-$1.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$2.22M +$286K +7,132 +17%
AQR Capital Management
27
AQR Capital Management
Connecticut
$2.17M +$311K +7,755 +19%
Charles Schwab
28
Charles Schwab
California
$2.04M – – –
Goldman Sachs
29
Goldman Sachs
New York
$2.04M +$329K +8,190 +22%
First Manhattan
30
First Manhattan
New York
$1.98M – – –
Two Sigma Investments
31
Two Sigma Investments
New York
$1.9M +$75.9K +1,889 +5%
TC
32
TFS Capital
Pennsylvania
$1.85M -$479K -11,920 -23%
DCM
33
DAFNA Capital Management
California
$1.81M – – –
GC
34
Globeflex Capital
California
$1.61M +$1.41M +35,155 New
American Century Companies
35
American Century Companies
Missouri
$1.6M -$853K -21,235 -38%
PNC Financial Services Group
36
PNC Financial Services Group
Pennsylvania
$1.58M -$3.06M -76,314 -69%
PI
37
Putnam Investments
Massachusetts
$1.52M -$852K -21,214 -39%
BA
38
BlackRock Advisors
Delaware
$1.19M +$13.3K +332 +1%
BCM
39
Bridgeway Capital Management
Texas
$1.14M – – –
Two Sigma Advisers
40
Two Sigma Advisers
New York
$1.03M -$153K -3,800 -14%
SCA
41
Secor Capital Advisors
New York
$1.03M +$234K +5,832 +35%
CCM
42
Cadence Capital Management
Massachusetts
$970K -$5.98K -149 -0.7%
BIM
43
BlackRock Investment Management
Delaware
$969K -$6.91K -172 -0.8%
ACM
44
Ativo Capital Management
Illinois
$895K – – –
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$812K +$40.2K +1,000 +6%
MCM
46
Matarin Capital Management
New York
$793K -$247K -6,152 -26%
IP
47
Isthmus Partners
Wisconsin
$782K +$13.9K +346 +2%
FQ
48
First Quadrant
California
$738K +$589K +14,660 +977%
TAM
49
Tocqueville Asset Management
New York
$731K -$161K -4,000 -20%
GA
50
Geneva Advisors
Illinois
$642K -$602 -15 -0.1%
1
2
3 4

BSTC Hedge Fund Activity: Q3 2016 in Review

90 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q3 2016, worth a combined $174M — up 11% from $156M a quarter earlier.

Fund positioning in BSTC was balanced in Q3 2016: 6 funds opened new positions, 6 closed out, 37 added to existing stakes and 30 trimmed.

The largest buyer was Northpointe Capital, opening a new position worth an estimated $4.97M. The largest seller was RK Capital Management (Colorado), cutting an estimated $3.44M.

  • 90 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $174M of BioSpecifics Technologies Corp. stock for Q3 2016, up 11% quarter-over-quarter.
  • 6 funds opened new BioSpecifics Technologies Corp. positions in Q3 2016 and 6 closed out, a net change of 0 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q3 2016 was Northpointe Capital, an estimated $4.97M added.
  • The largest BioSpecifics Technologies Corp. seller in Q3 2016 was RK Capital Management (Colorado), an estimated $3.44M sold.

Based on aggregated 13F filings for Q3 2016.